NABI Financial Facts
Basic income (loss) per share: -0.26Diluted income (loss) per share: -0.26
See Full Income Statement
Total liabilities: 26.5M
Total assets: 63.1M
See Full Balance Sheet
Nabi Biopharmaceuticals (NABI) Earnings
|
Expand Research on NABI
| Next EPS Date | N/A | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +54.2% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -3.2% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/8/12  |
Q312 | -$0.12 | N/A | N/A | $632K | $1.1M | N/A |  | | Details | |
| 8/9/12 |
Q212 | -$0.06 | -$0.11 | +$0.05 | $631K | $3.7M | N/A | | | Details | |
| 5/10/12 | Q112 | -$0.03 | N/A | N/A | $600K | $9.17M | N/A | | | Details | |
| 3/14/12 |
Q411 | -$0.05 | N/A | N/A | N/A | N/A | N/A | | | Details | |
| 11/2/11 |
 |
Q311 | -$0.07 | -$0.09 | +$0.02 | $1.1M | $5M | N/A | | | Details |
| 8/3/11 |
|
Q211 | -$0.11 | -$0.14 | +$0.03 | $3.7M | $3.54M | N/A | | | Details |
| 5/5/11 |
|
Q111 | $0.05 | -$0.18 | +$0.23 | $9.1M | $2.54M | N/A | | | Details |
| 3/8/11 | Q410 | -$0.15 | -$0.08 | -$0.07 | $4.08M | $5.99M | N/A | | | Details |
